Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
LPAR5 encodes a member of the rhodopsin class of G protein-coupled transmembrane receptors. De plus, nous expédions Lysophosphatidic Acid Receptor 5 Anticorps (32) et Lysophosphatidic Acid Receptor 5 Protéines (5) et beaucoup plus de produits pour cette protéine.
These results suggest that the diverse roles of LPA4 (Montrer LPAR4 Kits ELISA), LPA5 and LPA6 (Montrer LPAR6 Kits ELISA) are involved in the activation of tumor progression in pancreatic cancer cells.
Down-regulation of LPA receptor 5 contributes to aberrant LPA signalling in EBV-associated nasopharyngeal carcinoma.
MMP-2 (Montrer MMP2 Kits ELISA) and MMP-9 (Montrer MMP9 Kits ELISA) were found in HT1080L5 cells, in comparison with control cells. These results suggest that LPA (Montrer APOA Kits ELISA) signaling via LPA5 negatively regulates the cell motile and invasive activities of human sarcoma cells.
These results suggest that LPA5 may act as a negative regulator of cellular responses in mouse fibroblast 3T3 cells, similar to the case for LPA1 (Montrer LPAR1 Kits ELISA).
It was shown that lysophosphatidic acid 5 receptor transactivated the epidermal growth factor receptor (Montrer EGFR Kits ELISA) and that inhibition of epidermal growth factor receptor (Montrer EGFR Kits ELISA) blocked lysophosphatidic acid 5 receptor-dependent activation of NHE3 (Montrer SLC9A3 Kits ELISA).
LPA5 is a bona fide LPA (Montrer APOA Kits ELISA) receptor on human mast cells responsible for the majority of LPA (Montrer APOA Kits ELISA) induced MIP-1beta (Montrer CCL4 Kits ELISA) release.
LPA4 (Montrer LPAR4 Kits ELISA) and LPA5 receptors induce osteoblastic differentiation of human mesenchymal stem cells
Data show that CLL cells express LPA receptors LPA(1-5) and VEGF receptors, and the plasma levels of VEGF are elevated in CLL patients.
GPR92 is proposed as a fifth LPA (Montrer APOA Kits ELISA) receptor, LPA5, which likely has distinct physiological functions in view of its expression pattern.
FPP (Montrer FDFT1 Kits ELISA) and NAG (Montrer NAGLU Kits ELISA) play a role in the sensory nervous system through activation of GPR92
These findings suggest that tumor and stromal LPA receptors, in particular LPA1 (Montrer LPAR1 Kits ELISA) and LPA5, play different roles in invasion and the seeding of metastasis
Lysophosphatidic acid receptor 5 inhibits B cell antigen receptor signaling and antibody response
These data expand the influences of LPA signaling in neuropathic pain through a second LPA receptor subtype, LPA(5), involving a mechanistically distinct downstream signaling pathway compared with LPA(1 (Montrer LPAR1 Kits ELISA)).
Lysophosphatidic acid (LPA) is a potent stimulant of NHE3 (Montrer SLC9A3 Kits ELISA) and fluid absorption in the intestine, signaling through LPA(5). Regulation by LPA(5) depends on its interaction with NHERF2 (Montrer SLC9A3R2 Kits ELISA).
GPR92 is highly expressed in the lymphocyte compartment of the gastrointestinal tract
Our data indicate that GPR93 can contribute to the observed induction of CCK expression and secretion by peptone and provide evidence that G protein-coupled receptors can transduce dietary luminal signals.
This gene encodes a member of the rhodopsin class of G protein-coupled transmembrane receptors. This protein transmits extracellular signals from lysophosphatidic acid to cells through heterotrimeric G proteins and mediates numerous cellular processes. Many G protein receptors serve as targets for pharmaceutical drugs. Transcript variants of this gene have been described.
G protein-coupled receptor 92
, G-protein coupled receptor 92
, G-protein coupled receptor 93
, LPA receptor 5
, lysophosphatidic acid receptor 5
, putative G protein-coupled receptor 92